StockData
Inhibitor Therapeutics, Inc. logo

Inhibitor Therapeutics, Inc. (INTI) company profile

INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.11+0.00 (+0.09%)

Close on Oct 19, 2026Market cap $19.06MP/E –Yield –

About Inhibitor Therapeutics

Pharmaceutical Preparations, SIC 2834

Inhibitor Therapeutics, Inc. is a pharmaceutical development company that focuses on repurposing approved active pharmaceutical ingredients to treat rare diseases, primarily targeting basal cell carcinoma nevus syndrome (Gorlin Syndrome). The company's lead development program centers on an oral formulation of itraconazole, an antifungal agent with anti-angiogenic properties that inhibit vascular growth supporting tumor proliferation. Its primary development candidate is a proprietary micronized and amorphous formulation developed to improve drug bioavailability and absorption for chronic disease management. The company currently operates without commercialized products, directing its activities toward preclinical and clinical evaluation to serve patients managed by dermatologists and Mohs micrographic surgeons.

The company operates primarily within the United States, targeting a domestic patient population of approximately 11,000 individuals with Gorlin Syndrome and an estimated prescriber base of 1,000 to 1,500 specialized Mohs surgeons. Inhibitor Therapeutics conducts its operations with two full-time employees and six part-time employees. It maintains its principal executive offices in Tampa, Florida.

Summary of the business section of Inhibitor Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Inhibitor Therapeutics, Inc.
Founded
1992
Headquarters
Tampa, FL
Address
4830 W. Kennedy Blvd., Suite 600 33609
Phone
(813) 766-2462
Employees
2, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Cherry Bekaert LLP, Tampa, Florida

Stock & identifiers

Ticker
INTI
Former tickers
HPPI until May 9, 2019
Exchange
OTC
IPO date
Sep 13, 2013
Shares outstanding
174M, Aug 14, 2026
Public float
$3.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1042418
FIGI
BBG000BW1GY2
Share class FIGI
BBG001SBC1N1
EIN
54-1641133

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Francis E. Odonnell JrChief Executive Officer, Director85,777,069
James A. McNultyChief Financial Officer46,002,114
Michelle YanezDirector1,221,271
Samuel P. Sears JrDirector1,229,543
Ronald E. OsmanDirector23,554,985
Michael Allen JermanDirector180,411
Niraj VasishtDirector200,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.12M$1.12M$353.36K$46–
FY2024$1.14M$1.14M$359.76K$61–
FY2023$1.09M$1.09M$337.96K$93–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOtherTotalvs. prior year
Francis E. O’Donnell
Executive Chairman and Chief Executive Officer
$598.00K$507.36K$13.27K$1.12M-2%
James A. McNulty
Interim Chief Financial Officer, Secretary and Treasurer
$200.00K$138.49K$24.09K$362.57K+1%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of the date of this Report, we have two full-time employees and six part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 12, 2019Name changeName changed from HedgePath Pharmaceuticals, Inc. to Inhibitor Therapeutics, Inc.
Mar 31, 2014Late filingNotification of late filing
Aug 28, 2013Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 16, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 20, 2013Name changeName changed from COMMONWEALTH BIOTECHNOLOGIES INC to HedgePath Pharmaceuticals, Inc.
May 15, 2013Late filingNotification of late filing
Apr 18, 2013BankruptcyBankruptcy or receivership (8-K Item 1.03)
Apr 1, 2013Late filingNotification of late filing
Mar 28, 2013Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 4, 2013Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 13, 2012Late filingNotification of late filing
Aug 14, 2012Late filingNotification of late filing
Mar 30, 2012Late filingNotification of late filing
Jan 5, 2012Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 12, 2011Late filingNotification of late filing
May 16, 2011Late filingNotification of late filing
Mar 14, 2011DeregistrationTermination of SEC registration (Form 15)
Jan 25, 2011BankruptcyBankruptcy or receivership (8-K Item 1.03)
Apr 13, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 9, 2010DelistingNotice of delisting from exchange (Form 25)
Jan 21, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 6, 2009Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 21, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 4, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 10, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 24, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 21, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 13, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 6, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 25, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)

See a number that looks wrong?